Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 131,032

Document Document Title
WO/2018/091937A1
The invention relates to the field of retinoid X receptor (RXR) signalling and a novel vitamin A pathway called Vitamin A5 pathway. Compounds which are useful to provide (R) 9-cis-13,14-dihydro-retinoic acid an endogenous RXR ligand are ...  
WO/2018/094076A1
The present invention is based on the seminal discovery of a panel of targeting peptides and antibodies that can recognize AD brains at different stages of the disease, starting from early to advanced stage. The peptide probes described ...  
WO/2018/091566A1
The invention relates to PUFA, vitamin E, vitamin D and the protein bound amino acids glycine, arginine and tryptophan as active ingredients for use in therapy of patients with COPD, neurological diseases or disorders and/or wounds, wher...  
WO/2018/090982A1
Provided are a benzodicycloalkane derivative, and a preparation method and use thereof. In particular, provided is a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method th...  
WO/2018/093957A1
Provided herein are therapeutic and/or prophylactic compounds for mitochondrial or oxidative stress diseases such as cancer, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, Machado-Joseph disease, spinocerebellar ataxia, Huntin...  
WO/2018/092921A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions ...  
WO/2018/090848A1
A Chinese medicine granule for invigorating the spleen, removing obstruction in collaterals and detoxification. The Chinese medicine granule comprising: 20-40 g of astragalus membranaceus, 10-25 g of tangshen, 10-20 g of bighead astracty...  
WO/2018/094116A1
Methods are provided of identifying a subject having impaired aldehyde dehydrogenase activity; and administering to the subject a compound comprising an isotopicaliy-modified polyunsaturated fatty acid, an isotopicaliy-modified polyunsat...  
WO/2018/089863A1
Lozenges comprising ethyl cellulose and cannabinoids for rapid and efficient delivery of medical cannabinoids are provided. The lozenge is suitable for administration of the cannabinoid(s) through the oral mucosa to the bloodstream. Embo...  
WO/2018/089561A1
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and progressive conditions such as Parkinson's disease. Such conditions may be caused by disease, be symptom...  
WO/2018/086534A1
The present invention relates to a vortioxetine hydrobromide long-acting injection preparation. The preparation comprises vortioxetine hydrobromide, a suspending agent, a stabilizer, a buffering agent, a pH regulator, and a solvent. The ...  
WO/2018/087082A1
The present invention refers to the use of compounds derived from trisubstituted 1H-pyrrole rings and aromatic rings, which have the following formula (I); wherein R1and R2 represent, independently of each other: an optionally substitute...  
WO/2018/089330A2
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseas...  
WO/2018/087656A1
The present invention relates to pharmaceutical compositions comprising NGF or molecules with NGF-like activity for use in the treatment of traumatic brain injury by means of intranasal administration, a method for treating traumatic bra...  
WO/2018/087361A1
The present invention relates to a pharmaceutical composition comprising dexketoprofen or a pharmaceutically acceptable salt thereof in combination with eletriptan or a pharmaceutically acceptable salt thereof and at least one pharmaceut...  
WO/2018/087018A1
The present invention relates to a compound of formula I, HetAr is a five or six membered heteroaryl group, selected from wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and may be the sa...  
WO/2018/088566A1
Provided are a novel HIF inhibitor, and a therapeutic or prophylactic drug for ischemic disease, glaucoma, optic nerve disease, retinal degenerative disease, angiogenic retinal disease, cancer, neurodegeneration, or autoimmune disease, w...  
WO/2018/089330A3
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseas...  
WO/2018/089328A1
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or m...  
WO/2018/089902A1
The disclosure relates to diaminothiazole derivatives of formula (I) where the variables are as defined herein, pharmaceutical compositions containing such compounds, and methods for the use of such compounds and compositions for the tre...  
WO/2018/086501A1
A novel ironing moxibustion apparatus combining moxibustion and ironing methods. Before and after use, the variation value of a grease parameter in a grease-containing Artemisia vulgaris product is less than 50% (0.5), wherein a grease c...  
WO/2018/086446A1
Disclosed is a substituted quinazoline compound having blood-brain barrier penetration capability. The structural formula of the compound is as represented by formula (I). The substituted quinazoline compound of the present invention, an...  
WO/2018/089702A1
The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDN...  
WO/2018/085886A1
A method of conditioning near term livestock population to minimise the mortality rate of an offspring population derived therefrom including providing caffeine or a methylxanthine compound to pregnant livestock population before, during...  
WO/2018/087202A1
The present invention relates to the use of compounds or pharmaceutical compositions comprising the same for use in the prophylaxis and/or treatment of alopecia areata, vitiligo, cutaneous lupus, lupus nephritis, giant cell arteritis, sa...  
WO/2018/090054A1
The present invention provides methods for treating Parkinson' s Disease (PD), e.g., PD associated with a genetic mutation in a glucocerebrosidase (GBA) gene or a leucine rich repeat kinase 2 (LRRK2) gene. The methods comprise administer...  
WO/2018/086498A1
A pharmaceutical composition, comprising a pharmaceutical active ingredient consisting of dexmedetomidine hydrochloride and ketamine hydrochloride. The pharmaceutical composition of the present invention has a synergistic effect, and the...  
WO/2018/082596A1
Provided herein are crystalline forms of ( ( ( ( (1r, 3R, 5S, 7r) -3, 5-dimethyladamantan-1-yl)carbamoyl) oxy) methyl benzoate (Compound (I)) : Also provided are compositions comprising the crystalline forms of Compound (I), processes of...  
WO/2018/083695A2
The invention generally concerns methods and formulations utilized in the methods which comprise cannabis plant extracts and copaxone.  
WO/2018/082034A1
Disclosed herein is a novel use of a triterpenoid mixture for the treatment of multiple sclerosis (MS). The triterpenoid mixture consists of, ganoderic acid A (GAA), ganoderic acid B (GAB), ganoderic acid C (GAC), ganoderic acid C5 (GAC5...  
WO/2018/085803A1
Disclosed herein are pyrido[3',2':4,5]thieno[2,3-d]pyridazin-8-amine and thieno[2,3-c:4,5-d']dipyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Als...  
WO/2018/085521A3
The present invention is directed to a novel method of treating a disease or condition mediated by modulation of Nav1.7 and other voltage-gated sodium channel subtypes, such as pain, in particular neuropathic pain, most particularly trig...  
WO/2018/082814A1
The invention relates to 5-amino-2,3-dihydro-1,4-phthalazinedione or related compounds, compositions or combinations thereof, for use in the treatment of chronic progressive multiple sclerosis, in particular primary and secondary progres...  
WO/2018/083098A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/083171A1
The invention relates to heterocyclic compounds of formula (I) as SIP modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment or alleviation of diseases or disorders mediated by an SIP receptor.  
WO/2018/083697A1
The invention generally concerns and methods of using glatiramer acetate (GA) and cannabidiol (CBD), for treating, preventing, ameliorating or delaying MS, and side effects associated with MS treatment.  
WO/2018/085486A9
Pharmaceutical compositions, kits and methods for treating tumors such as glioma and cancers such as leukemia with (R)-2-hydroxyglutarate (R-2HG) are provided, along with therapeutic regimens including treatment of a patient suffering fr...  
WO/2018/085521A9
The present invention is directed to a novel method of treating a disease or condition mediated by modulation of Nav1.7 and other voltage-gated sodium channel subtypes, such as pain, in particular neuropathic pain, most particularly trig...  
WO/2018/083051A1
The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairm...  
WO/2018/082557A1
Disclosed herein are inclusion complexes comprising vilazodone or a pharmaceutically acceptable salt thereof and an inclusion material, compositions and pharmaceutical formulations comprising the inclusion complexes, and methods for prep...  
WO/2018/083247A1
The present invention relates to 4,4a,5,7-tetrahydro-3H-furo[3,4-b]pyridinyl compound inhibitors of beta-site APP-cleaving enzyme having the structure shown in Formula (I) wherein the radicals are as defined in the specification. The inv...  
WO/2018/085476A1
The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering fr...  
WO/2018/083101A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/083695A3
The invention generally concerns methods and formulations utilized in the methods which comprise cannabis plant extracts and copaxone.  
WO/2018/083050A1
The present invention relates to a compound of formula I, 1-1 or 1-2 wherein R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, or lower alkoxy substituted by halogen; R1may be different if n = 2 or 3...  
WO/2018/083223A1
The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.  
WO/2018/085486A1
Pharmaceutical compositions, kits and methods for treating tumors such as glioma and cancers such as leukemia with (R)-2-hydroxyglutarate (R-2HG) are provided, along with therapeutic regimens including treatment of a patient suffering fr...  
WO/2018/083103A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/085263A1
Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that can metabolize under physiological conditions to ornithine. The pH and plasma stability of compounds of formula (II...  
WO/2018/081018A1
A method is disclosed of treating pain with senicapoc, a potent Ca2+- activated K+ channel, Kca3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-Ιβ and NO release from microglia cells vivo and in...  

Matches 501 - 550 out of 131,032